Composting paper and grass clippings with anaerobically treated palm oil mill effluent

Purpose The purpose of this study is to investigate the composting performance of anaerobically treated palm oil mill effluent (AnPOME) mixed with paper and grass clippings. Methods Composting was conducted using a laboratory scale system for 40 days. Several parameters were determined: temperature, mass reduction, pH, electrical conductivity, colour, zeta potential, phytotoxicity and final compost nutrients. Results The moisture content and compost mass were reduced by 24 and 18 %, respectively. Both final compost pH value and electrical conductivity were found to increase in value. Colour (measured as PtCo) was not suitable as a maturity indicator. The negative zeta potential values decreased from −12.25 to −21.80 mV. The phytotoxicity of the compost mixture was found to decrease in value during the process and the final nutrient value of the compost indicates its suitability as a soil conditioner. Conclusions From this study, we conclude that the addition of paper and grass clippings can be a potential substrate to be composted with anaerobically treated palm oil mill effluent (AnPOME). The final compost produced is suitable for soil conditioner

Space Velocities of L- and T-type Dwarfs

(Abridged) We have obtained radial velocities of a sample of 18 ultracool dwarfs (M6.5-T8) using high-resolution, near-infrared spectra obtained with NIRSPEC and the Keck II telescope. We have confirmed that the radial velocity of Gl 570 D is coincident with that of the K-type primary star Gl 570 A, thus providing additional support for their true companionship. The presence of planetary-mass companions around 2MASS J05591914-1404488 (T4.5V) has been analyzed using five NIRSPEC radial velocity measurements obtained over a period of 4.37 yr. We have computed UVW space motions for a total of 21 L and T dwarfs within 20 pc of the Sun. This population shows UVW velocities that nicely overlap the typical kinematics of solar to M-type stars within the same spatial volume. However, the mean Galactic (44.2 km/s) and tangential (36.5 km/s) velocities of the L and T dwarfs appear to be smaller than those of G to M stars. A significant fraction (~40%) of the L and T dwarfs lies near the Hyades moving group (0.4-2 Gyr), which contrasts with the 10-12% found for earlier-type stellar neighbors. Additionally, the distributions of all three UVW components (sigma_{UVW} = 30.2, 16.5, 15.8 km/s) and the distributions of the total Galactic (sigma_{v_tot} = 19.1 km/s) and tangential (sigma_{v_t} = 17.6 km/s) velocities derived for the L and T dwarf sample are narrower than those measured for nearby G, K, and M-type stars, but similar to the dispersions obtained for F stars. This suggests that, in the solar neighborhood, the L- and T-type ultracool dwarfs in our sample (including brown dwarfs) is kinematically younger than solar-type to early M stars with likely ages in the interval 0.5-4 Gyr.Comment: Accepted for publication in Ap

Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia : Results From a UK National Register

The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts and can provide comments but have no input into determining the topics for analysis, publication and no input into the work involved in this analysis. This analysis is part-funded by Arthritis Research UK (Grant No: 21378)Peer reviewedPublisher PD

Chemical-looping combustion - a thermodynamic study

Published versio

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

BACKGROUND:Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. This study aims to define the role of a 1:1 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) cannabinoid preparation in the management of symptom burden in patients with advanced cancer undergoing standard palliative care. METHODS AND DESIGN:One hundred fifty participants will be recruited from five sites within the Queensland Palliative Care Research Group (QPCRG) and randomly assigned to an active treatment or placebo group. This study is a pragmatic multicentre, randomised, placebo-controlled, two-arm trial of escalating doses of an oral 1:1 THC/CBD cannabinoid preparation. It will compare efficacy and safety outcomes of a titrated dose (10 mg/10 mg/mL oral solution formulation, dose range 2.5 mg/2.5 mg-30 mg/30 mg/day) against placebo. There is a 2-week patient-determined titration phase, using escalating doses of 1:1 THC/CBD or placebo, to reach a dose that achieves symptom relief with tolerable side effects. This is then followed by a further 2-week assessment period on the stable dose determined in collaboration with clinicians. The primary objective is to assess the effect of escalating doses of a 1:1 THC/CBD cannabinoid preparation against placebo on change in total symptom score, with secondary objectives including establishing a patient-determined effective dose, the change in total physical and emotional sores, global impression of change, anxiety and depression, opioid use, quality of life and adverse effects. DISCUSSION:This will be the first placebo-controlled clinical trial to rigorously evaluate the efficacy, safety and acceptability of 1:1 THC/CBD for symptom relief in advanced cancer patients. This study will allow the medical community to have some evidence to present to patients wishing to access cannabis for their symptoms caused by advanced malignancy. TRIAL REGISTRATION:ACTRN, ACTRN12619000037101 . Registered on 14 January 2019. Trial Sponsor: Mater Misericordiae Limited (MML) and Mater Medical Research Institute Limited (MMRI)-Raymond Terrace, South Brisbane, Brisbane, QLD, Australia

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: A double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD)

© 2019 The Author(s). Background: Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids, but there is little high quality evidence to guide clinicians. This study aims to define the role of cannabidiol (CBD) in the management of symptom burden in patients with advanced cancer undergoing standard palliative care. Methods and design: This study is a multicentre, randomised, placebo controlled, two arm, parallel trial of escalating doses of oral CBD. It will compare efficacy and safety outcomes of a titrated dose of CBD (100 mg/mL formulation, dose range 50 mg to 600 mg per day) against placebo. There is a 2-week patient determined titration phase, using escalating doses of CBD or placebo to reach a dose that achieves symptom relief with tolerable side effects. This is then followed by a further 2-week assessment period on the stable dose determined in collaboration with clinicians. Discussion: A major strength of this study is that it will target symptom burden as a whole, rather than just individual symptoms, in an attempt to describe the general improvement in wellbeing previously reported by some patients in open label, non controlled trials of medicinal cannabis. Randomisation with placebo is essential because of the well-documented over reporting of benefit in uncontrolled trials and high placebo response rates in cancer pain trials. This will be the first placebo controlled clinical trial to evaluate rigorously the efficacy, safety and acceptability of CBD for symptom relief in advanced cancer patients. This study will provide the medical community with evidence to present to patients wishing to access medicinal cannabis for their cancer related symptoms. Trial registration number: ALCTRN12618001220257 Registered 20/07/2018

Predicting convective blueshift and radial-velocity dispersion due to granulation for FGK stars

To detect Earth-mass planets using the Doppler method, a major obstacle is to differentiate the planetary signal from intrinsic stellar variability (e.g., pulsations, granulation, spots and plages). Convective blueshift, which results from small-scale convection at the surface of Sun-like stars, is relevant for Earth-twin detections as it exhibits Doppler noise on the order of 1 m/s. Here, we present a simple model for convective blueshift based on fundamental equations of stellar structure. Our model successfully matches observations of convective blueshift for FGK stars. Based on our model, we also compute the intrinsic noise floor for stellar granulation in the radial velocity observations. We find that for a given mass range, stars with higher metallicities display lower radial-velocity dispersion due to granulation, in agreement with MHD simulations. We also provide a set of formulae to predict the amplitude of radial-velocity dispersion due to granulation as a function of stellar parameters. Our work is vital in identifying the most amenable stellar targets for EPRV surveys and radial velocity follow-up programmes for TESS, CHEOPS, and the upcoming PLATO mission.Comment: 11 pages, 5 figures, 3 tables. Submitted, under revie

The effect of sinoaortic denervation on renal wrap hypertension

The purpose of this study was to determine whether sinoaortic deafferentation (SAD) alters the severity of hypertension or sympathoadrenal contribution to mean blood pressure (MAP) during renal wrap hypertension. Male Sprague-Dawley rats were implanted with radiotelemetry transmitters for 24-hour recording of MAP and heart rate. All rats underwent either SAD or sham SAD (Intact) surgery and were allowed to recover for 10 to 14 days. The rats were then assigned to a normotensive (Sham) group or a hypertensive (Wrap) group in which 1-kidney figure-8 renal wrap was performed. SAD increased the acute MAP response to renal wrap (Intact-Sham=5+/-1 mm Hg, Intact-Wrap=45+/-3 mm Hg, SAD-Sham=3+/-3 mm Hg, SAD-Wrap=58+/-4 mm Hg) and increased the lability of MAP (SD of MAP; Intact-Sham=3.8+/-0.2, Intact-Wrap=4.2+/-0.3, SAD-Sham=9. 6+/-1.4, SAD-Wrap=9.7+/-1.4). MAP was not different between SAD and Intact rats during 4 weeks after renal wrap or sham surgery; however, induction of hypertension produced additional MAP variability that was independent of SAD (Intact-Sham=4.6+/-0.4, Intact-Wrap=6.2+/-0.6, SAD-Sham=6.3+/-0.5, SAD-Wrap=10.8+/-1.5). In a separate group of rats, the sympathoadrenal contribution to MAP was assessed by the depressor response to ganglionic blockade and plasma norepinephrine at rest and after neuronal uptake inhibition with desipramine. The depressor response to ganglionic blockade was significantly increased by renal wrap and by SAD (Intact-Sham=-49+/-2 mm Hg, Intact-Wrap=-73+/-4 mm Hg, SAD-Sham=-77+/-5 mm Hg, SAD-Wrap=-96+/-6 mm Hg). In the 3 groups with enhanced ganglionic blockade responses, desipramine caused a significant increase in plasma norepinephrine. These results indicate that SAD does not alter the development of renal wrap hypertension but does increase the sympathoadrenal contribution to MAP in both normotensive and hypertensive animal

The incidence and risk factors for new onset atrial fibrillation in the PROSPER study

Aims Atrial fibrillation/flutter (AF) is the most common arrhythmia in older people. It associates with reduced exercise capacity, increased risk of stroke, and mortality. We aimed to determine retrospectively whether pravastatin reduces the incidence of AF and whether any electrocardiographic measures or clinical conditions might be risk factors for its development. Methods and results The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a randomized, double-blind controlled trial that recruited 5804 individuals aged 70-82 years with a history of, or risk factors for, vascular disease. A total of 2891 were allocated to pravastatin and 2913 to placebo; mean follow-up was 3.2 years. Electrocardiograms (ECGs), which were recorded at baseline, annually thereafter, and at run-out, were processed by computer and reviewed manually. In all, 264 of 2912 (9.1%) of the placebo group and 283 of 2888 (9.8%) of the pravastatin-treated group developed AF [hazard ratio 1.08 (0.92,1.28), P = 0.35)]. Multivariate analysis showed that PR and QTc intervals, age, left ventricular hypertrophy, and ST-T abnormalities were related to development of AF after adjustment for many variables including alcohol consumption, which itself was univariately predictive of developing AF. Previous myocardial infarction on the ECG was not a risk factor. A history of vascular disease was strongly linked with developing AF but not diabetes and hypertension. Conclusion Pravastatin does not reduce the incidence of AF in older people at risk of vascular disease, at least in the short-medium term. Risk factors for AF include older age, prolongation of PR or QTc intervals, left ventricular hypertrophy, and ST-T abnormalities on the EC